Mei Pharma Stock Earnings Per Share
| MEIP Stock | USD 2.31 0.01 0.43% |
MEI Pharma fundamentals help investors to digest information that contributes to MEI Pharma's financial success or failures. It also enables traders to predict the movement of MEI Stock. The fundamental analysis module provides a way to measure MEI Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MEI Pharma stock.
MEI |
MEI Pharma Company Earnings Per Share Analysis
MEI Pharma's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current MEI Pharma Earnings Per Share | (5.73) X |
Most of MEI Pharma's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MEI Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, MEI Pharma has an Earnings Per Share of -5.73 times. This is 168.46% lower than that of the Biotechnology sector and 19.62% higher than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
MEI Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MEI Pharma's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MEI Pharma could also be used in its relative valuation, which is a method of valuing MEI Pharma by comparing valuation metrics of similar companies.MEI Pharma is currently under evaluation in earnings per share category among its peers.
MEI Fundamentals
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (22.42 M) | ||||
| Shares Outstanding | 6.66 M | ||||
| Shares Owned By Insiders | 1.31 % | ||||
| Shares Owned By Institutions | 40.60 % | ||||
| Number Of Shares Shorted | 4.18 K | ||||
| Price To Earning | 30.29 X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 0.27 X | ||||
| Revenue | 65.3 M | ||||
| Gross Profit | (10.86 M) | ||||
| EBITDA | 26.38 M | ||||
| Net Income | 17.78 M | ||||
| Cash And Equivalents | 153.25 M | ||||
| Cash Per Share | 1.15 X | ||||
| Total Debt | 8.36 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | 3.32 X | ||||
| Cash Flow From Operations | (50.47 M) | ||||
| Short Ratio | 0.82 X | ||||
| Earnings Per Share | (5.73) X | ||||
| Price To Earnings To Growth | 20.60 X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 28 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 15.32 M | ||||
| Total Asset | 41.38 M | ||||
| Retained Earnings | (388.22 M) | ||||
| Working Capital | 32.41 M | ||||
| Current Asset | 46.75 M | ||||
| Current Liabilities | 5.51 M | ||||
| Net Asset | 41.38 M |
About MEI Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MEI Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MEI Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MEI Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.